15 results on '"Lim, Lyndell L."'
Search Results
2. The Humira in Ocular Inflammations Taper (HOT) Study
- Author
-
Pichi, Francesco, Smith, Scott D., Goldstein, Debra A., Baddar, Dina, Gerges, Terese K.A., Janetos, Timothy M., Ruiz-Cruz, Matilde, Elena Concha-del-Río, Luz, Maruyama, Kazuichi, Carina ten Berge, Josianne, Rombach, Saskia M., Cimino, Luca, Bolletta, Elena, Miserocchi, Elisabetta, Scandale, Pierluigi, Serafino, Massimiliano, Camicione, Paola, Androudi, Sofia, Gonzalez-Lopez, Julio J., Lim, Lyndell L., Singh, Nandini, Gupta, Vishali, Gupta, Nikita, Amer, Radgonde, Dodds, Emilio M., Inchauspe, Sebastian, Munk, Marion R., Donicova, Emilia, Carreño, Ester, Takeuchi, Masaru, Chee, Soon-Phaik, Chew, Milton C., Agarwal, Aniruddha, Schlaen, Ariel, Gómez, Ramiro A., Couto, Cristobal A., Khairallah, Moncef, and Neri, Piergiorgio
- Published
- 2024
- Full Text
- View/download PDF
3. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma
- Author
-
Androudi, Sofia, Apivatthakakul, Atitaya, Arevalo, Fernando J., Berkenstock, Meghan K., Carreño, Ester, Chee, Soon-Phaik, Choovuthayakorn, Janejit, Cimino, Luca, Cornish, Elisa E., Farrall, Alexandra L., Gehl, Zsuzsanna, Gentile, Pietro, Gerges, Terese K., Gozzi, Fabrizio, Hernández-Pons, Antonio, Issa, Samar, Kim, Hyeong Min, Kim, Min, Knickelbein, Jared E., Kunavisarut, Paradee, Lee, Seung M., Lim, Lyndell L., Lin, Ming Lee, Llorenç, Victor, López-Sierra, Sara, Martínez-Costa, Lucía, McCluskey, Peter, Mochizuki, Manabu, O'Day, Roderick F., Pai, Amy S., Palestine, Alan G., Pathanapitoon, Kessara, Radford, Mark H.B., Silpa-Archa, Sukhum, Smith, Justine R., Terada, Yukiko, Waduthantri, Samanthila, Weaver, Travers R.E., Williams, Keryn L., Woo, Se Joon, and Younan, Christine
- Published
- 2024
- Full Text
- View/download PDF
4. Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.
- Author
-
Sura, Amol A., Sun, Yuwei, Reddy, Amit K., Rathinam, S. R., Gonzales, John A., Thundikandy, Radhika, Vedhanayaki, Rajesh, Kanakath, Anuradha, Murugan, Bala, Doan, Thuy A., Lim, Lyndell L., Suhler, Eric B., Al-Dhibi, Hassan A., and Acharya, Nisha R.
- Subjects
MYCOPHENOLIC acid ,STEROID drugs ,METHOTREXATE ,UVEITIS ,ODDS ratio - Abstract
Some patients taking methotrexate (MTX) or mycophenolate mofetil (MMF) experience intolerable side effects at full doses. We evaluated whether dose reduction affected treatment outcomes in uveitis patients. Subanalysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Patients were randomized to receive MTX (25 mg weekly) or MMF (3 g daily). A pre-specified dose reduction protocol could be employed for intolerable side effects. Primary analysis was performed at 6 months. 43/194 patients (22%) required dose reduction. 88/151 patients (58%) on maximum doses and 32/43 patients (74%) on reduced doses were deemed treatment successes at 6 months. The odds ratio point estimate (1.60, 95% CI 0.72–3.74) favored dose-reduction but this was not significant. Following reduction, adverse events improved at the subsequent study visit (79 events reduced to 63 events). Dose reduction of antimetabolites was not associated with worse outcomes in this subanalysis of a uveitis trial. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Drug Retention Time of Immunosuppressive Therapy in Behcet’s Uveitis
- Author
-
Tran, Donald, primary, Rogers, Sophie, additional, and Lim, Lyndell L., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Insights into the diagnosis and management of sarcoid uveitis: A review.
- Author
-
Samalia, Priya D., Lim, Lyndell L., and Niederer, Rachael L.
- Subjects
- *
SARCOIDOSIS , *IRIDOCYCLITIS , *UVEITIS , *OPTICAL coherence tomography , *SYMPTOMS , *AGE factors in disease , *DIAGNOSIS - Abstract
Sarcoidosis is a leading cause of non‐infectious uveitis that commonly affects middle‐aged individuals and has a female preponderance. The disease demonstrates age, sex and ethnic differences in clinical manifestations. A diagnosis of sarcoidosis is made based on a compatible clinical presentation, supporting investigations and histologic evidence of non‐caseating granulomas, although biopsy is not always possible. Multimodal imaging with widefield fundus photography, optical coherence tomography and angiography can help in the diagnosis of sarcoid uveitis and in the monitoring of treatment response. Corticosteroid remains the mainstay of treatment; chronic inflammation requires steroid‐sparing immunosuppression. Features on multimodal imaging such as vascular leakage may provide prognostic indicators of outcome. Female gender, prolonged and severe uveitis, and posterior involving uveitis are associated with poorer visual outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites.
- Author
-
Chattopadhyay, Aheli, Rathinam, SR, Gonzales, John A., Kelly, Nicole K., Thundikandy, Radhika, Kanakath, Anuradha, Murugan, S. Bala, Vedhanayaki, R., Lim, Lyndell L., Suhler, Eric B., Al-Dhibi, Hassan A., Doan, Thuy, Ebert, Caleb D., Porco, Travis C., and Acharya, Nisha R.
- Subjects
VISUAL acuity ,CLINICAL trials ,ANTIMETABOLITES ,QUALITY of life ,UVEITIS - Abstract
To evaluate how changes in visual acuity are associated with changes in quality of life (QoL) among patients with non-infectious uveitis taking antimetabolites. This secondary analysis of the multicenter First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial involves 216 participants randomized to methotrexate or mycophenolate mofetil. Vision-related (NEI-VFQ and IND-VFQ) and health-related (PCS and MCS SF-36v2) QoL and visual acuity were measured at baseline and 6-month primary endpoint. Visual acuity was significantly associated and correlated with all QoL measures (Spearman correlation coefficients = 0.5, 0.5, 0.3, and 0.4 for NEI-VFQ, IND-VFQ, SF-36v2 MCS and PCS, respectively). All observed changes in QoL met or exceeded the minimal clinically important difference definition on each scale. Treatment group was not significantly associated with any QoL measure. By adding insight beyond visual acuity, QoL provides a more comprehensive picture of the patient experience during uveitis treatment. Abbreviations and Acronyms: QoL = quality of life; VR-QoL = vision-related quality of life; HR-QoL = health-related quality of life; FAST = First-line Antimetabolites as Corticosteroid Sparing Treatment; NEI-VFQ = National Eye Institute Visual Functioning Questionnaire; IND-VFQ = Indian Visual Functioning Questionnaire; SF-36v2 = Medical Outcomes Study 36-Item Short Form Survey; PCS = physical component score; MCS = mental component score; 95% CI = 95% confidence interval; MCID = minimal clinically important difference [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Acute posterior multifocal placoid pigment epitheliopathy: clinical presentation and risk of stroke and transient ischaemic attack.
- Author
-
Niederer, Rachael L., Samalia, Priya D., Yi-Hsing Chen, Goh, Jonathan K. S., Cornish, Elisa Eleanor, Guest, Stephen, McCluskey, Peter J., Lim, Lyndell L., Sims, Joanne L., Lightman, Susan, and Tomkins-Netzer, Oren
- Abstract
Background/aims Acute posterior multifocal placoid pigment epitheliopathy is a rare but important disease that can be associated with life-threatening complications due to cerebral vasculitis. The primary objective was to determine the incidence of neurological complications and risk factors for stroke and transient ischaemic attack (TIA) associated with acute posterior multifocal placoid pigment epitheliopathy. Secondary objectives included the clinical presentation, visual outcomes and recurrence rates. Methods This was a multicentre retrospective case series including 111 eyes from 60 subjects presenting from January 2009 to June 2020. Results Median age at presentation was 29 years (IQR 24.7-35.1) and 36 subjects (60.0%) were male. 20 subjects (33.3%) reported a viral prodrome. Stroke and TIA were observed in seven subjects (11.7%). Older age was the only significant risk factor for stroke/TIA (p=0.042). Vision loss occurred in seven eyes, with four eyes (3.6%) having final visual acuity 6/15-6/60 and three eyes (2.7%) having visual acuity of 6/60 or worse. Recurrence occurred in 10 subjects (16.7%). Conclusions The presence of headache cannot reliably predict those at risk of stroke/TIA. Individuals presenting with acute posterior multifocal pigment epitheliopathy should therefore undergo a clinical neurological review and work-up for cerebral vasculitis as deemed appropriate by the treating ophthalmologist and collaborating neurologist. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Intravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns.
- Author
-
Phakey, Sachin, Hall, Anthony J, and Lim, Lyndell L
- Subjects
RANIBIZUMAB ,MACULAR degeneration ,COVID-19 pandemic ,STAY-at-home orders ,INTRAVITREAL injections ,ENDOTHELIAL growth factors - Abstract
We investigate the impact of COVID-19 and lockdowns on anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD) in Victoria (Australian state with highest burden of COVID-19 in 2020) and Australia, by examining anti-VEGF prescriptions supplied for AMD treatment between 2018 and 2020. We performed a retrospective, population-based analysis of aflibercept and ranibizumab prescriptions supplied for the treatment of AMD in Victoria and Australia between 1 January 2018 and 31 December 2020, as recorded by the Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS, the Australian Government program subsidising medication costs for Australian residents and veterans. Poisson models and univariate regression were used to descriptively examine trends in monthly anti-VEGF prescription rates with time and changes in monthly prescription rates (prescription rate ratios [RR]). In 2020, anti-VEGF AMD prescription rates in Victoria decreased by 18% during the nationwide lockdown between March and May (RR 0.82, 95% CI: 0.80–0.85, p <.001), and by 24% during the Victorian-specific lockdown between July and October (RR 0.76, 95% CI: 0.73–0.78, p <.001). In Australia, prescription rates tended to decrease between January and October 2020, reducing by 25% (RR 0.75, 95% CI: 0.74–0.77, p <.001) between these months, including between March and April (RR 0.94, 95% CI: 0.92–0.95, p <.001) but not April and May (RR 1.10, 95% CI: 1.09–1.12, p <.001). In 2020, anti-VEGF prescriptions for AMD treatment decreased modestly in Victoria during both lockdowns and in Australia during the year. Decreases may represent reduced treatment because of COVID-19, including public health orders, patients' self-limiting care, and ophthalmologists treating-and-extending to maximum intervals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Increasing ocular syphilis and syphilis notifications in Australia and the state of Victoria between 2017 and 2022.
- Author
-
Phakey, Sachin, Lichtenstein, Jasmine, and Lim, Lyndell L.
- Subjects
SYPHILIS ,SEXUALLY transmitted diseases - Abstract
This article examines the increase in ocular syphilis cases and syphilis notifications in Australia and the state of Victoria between 2017 and 2022. The study found that ocular syphilis cases and syphilis notifications increased during this period, with a decrease in 2020 and 2021 likely due to the impact of the COVID-19 pandemic. The increase in syphilis rates may be higher than other sexually transmitted infections, and possible reasons include increased high-risk sexual practices, travel and migration, socioeconomic disparities, and increased testing. Ophthalmologists are advised to routinely test for syphilis in patients with newly-diagnosed uveitis, particularly among at-risk populations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
11. Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial
- Author
-
Mehta, Hemal, Lim, Lyndell L., Nguyen, Vuong, Qatarneh, Dania, Wickremasinghe, Sanjeewa S., Hodgson, Lauren A.B., Quin, Godfrey J., McAllister, Ian L., Gillies, Mark C., and Fraser-Bell, Samantha
- Published
- 2024
- Full Text
- View/download PDF
12. Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease.
- Author
-
Sundararajan, Miel, Rathinam, Sivakumar R., Thundikandy, Radhika, Kanakath, Anuradha, Balamurugan, S., Vedhanayaki, R., Miller, D. Claire, Lim, Lyndell L., Suhler, Eric B., Al-Dhibi, Hassan A., Arellanes-Garcia, Lourdes, Reddy, Amit K., Feng, Shu, Doan, Thuy, Porco, Travis C., Shantha, Jessica G., Acharya, Nisha R., and Gonzales, John A.
- Subjects
- *
OPTICAL coherence tomography , *RHODOPSIN , *MYCOPHENOLIC acid , *RANDOMIZED controlled trials , *VISUAL acuity - Abstract
AbstractPurposeMethodsResultsConclusionsThe choroidal thickening and serous retinal detachments that characterize Vogt-Koyanagi-Harada (VKH) disease can be imaged in detail using spectral domain optical coherence tomography (SD-OCT). Whether specific qualitative and quantitative SD-OCT features at presentation were associated with visual outcomes in a randomized controlled trial comparing methotrexate to mycophenolate for steroid-sparing control of uveitis were evaluated.An exploratory subanalysis of data from the FAST trial in which SD-OCT images from VKH participants were analyzed for presence/absence of bacillary detachments, retinal pigment epithelium (RPE) folds, and internal limiting membrane (ILM) fluctuations was performed. A modified RPE undulation index was calculated to provide a quantifiable surrogate marker for choroidal folds.SD-OCT images were available from 158 eyes with VKH. At baseline, bacillary detachments were present in 23.5% of eyes, RPE folds in 22.8% of eyes, and ILM fluctuations in 35.2% of eyes. For each 0.1 unit increase in modified RPE undulation index, there was an associated 0.13 increase in mean logMAR BSCVA at baseline. None of the SD-OCT features were associated with BSCVA at the 6-month primary endpoint. Indeed, mean final BSCVA was similar in those with and without the SD-OCT features of interest at baseline, and was between 0.1 and 0.2 logMAR (Snellen visual acuity 20/25 to 20/30).While eyes with VKH may present with a variety of SD-OCT imaging pathology prior to starting immunosuppression with methotrexate or mycophenolate mofetil, final visual outcome in our study was excellent. With appropriate immunosuppression, good visual outcomes are possible in VKH.ClinicalTrials.gov Identifier NCT01829295Date of Registration: April 11, 2013 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Elevated aqueous TNF‐α levels are associated with more severe functional and anatomic findings in eyes with diabetic macular oedema.
- Author
-
Chew, Sky, Tran, Tuan, Sanfilippo, Paul, Lim, Lyndell L., Sandhu, Sukhpal S., and Wickremasinghe, Sanjeewa
- Subjects
- *
DIABETIC retinopathy , *MACULAR edema , *RANIBIZUMAB , *ENDOTHELIAL growth factors , *VISUAL acuity - Abstract
Background Methods Results Conclusions Intravitreal ranibizumab for diabetic macular oedema (DMO) has been recently shown to modulate levels of aqueous cytokines. This study investigates the associations between changes in aqueous cytokine levels following intravitreal ranibizumab therapy and the corresponding anatomical and functional changes in the eye.Twenty‐five patients comprising 30 eyes diagnosed with DMO were prospectively recruited. All eyes received three loading dose ranibizumab injections at baseline, week 4 and week 8, followed by pro re nata treatment based on best‐corrected visual acuity (BCVA) and central macular thickness (CMT) up to week 48. Prior to ranibizumab administration, aqueous samples were collected from all eyes, and subsequent sampling was performed at week 8. Levels of 32 cytokines were assessed at baseline and at week 8.At baseline, higher aqueous TNF‐α levels were associated with poorer BCVA (p = 0.033), greater macular volume (p = 0.017) and worse diabetic retinopathy (p = 0.047). Higher levels of IL‐7 were associated with poorer BCVA and greater macular volume (MV). Following treatment with ranibizumab there was a significant correlation with reduction of aqueous TNF‐α and improvements in BCVA and MV, both at 6 months (BCVA [r = −0.558, p = 0.001], MV [r = 0.410, p = 0.024]) and 12‐months (BCVA [r = −0.413, p = 0.023], MV [r = 0.482, p = 0.008]). The change in VEGF concentration following ranibizumab treatment did not correlate with either BCVA or MV improvements (p > 0.05).Higher levels of aqueous TNF‐α and IL‐7 correlated with worse DMO, both anatomically and functionally. Reductions in levels of aqueous TNF‐α, but not VEGF, post ranibizumab treatment were associated with improvement in BCVA and MV. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Outcomes in Patients With Vogt-Koyanagi-Harada Disease From the First-Line Antimetabolites for Steroid-Sparing Treatment Uveitis Trial.
- Author
-
Acharya NR, Rathinam SR, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, Gonzales JA, Lim LL, Suhler EB, Al-Dhibi HA, Doan T, Arellanes-Garcia L, Coyne A, Porco TC, and Shantha JG
- Abstract
Purpose: To compare the effectiveness of methotrexate (MTX) and mycophenolate mofetil (MMF) in achieving corticosteroid-sparing control of uveitis in patients with Vogt-Koyanagi-Harada (VKH) disease., Methods: A subanalysis of patients with VKH from the First-line Antimetabolites as Steroid-sparing Treatment Uveitis Trial, a randomized, observer-masked, comparative effectiveness trial, with comparisons by treatment (MTX vs MMF) and disease stage (acute vs chronic). Individuals with noninfectious uveitis were placed on a standardized corticosteroid taper and block randomized 1:1 to either 25 mg weekly oral MTX or 1.5 g twice daily oral MMF. The primary outcome was treatment success defined by corticosteroid-sparing control of uveitis at 6 months. Additional outcomes included change in best spectacle-corrected visual acuity (BSCVA), retinal central subfield thickness (CST), and resolution of serous retinal detachment (SRD)., Results: Ninety-three out of 216 enrolled patients had VKH; 49 patients were randomized to MTX and 44 to MMF, of which 85 patients (46 on MTX, 39 on MMF) contributed to the primary outcome. There was no significant difference in treatment success by antimetabolite (80.4% for MTX compared to 64.1% for MMF; P = .12) or in BSCVA improvement (P = .78). MTX was superior to MMF in reducing CST (P = .003) and resolving SRD (P = .02). There was no significant difference in treatment success by disease stage (P = .25), but patients with acute VKH had greater improvement in BSCVA (P < .001) and reduction of CST (P = .02) than chronic VKH patients., Conclusions: MTX and MMF have comparable outcomes as corticosteroid-sparing immunosuppressive therapies for VKH. Visual acuity improvement was greater in acute vs chronic VKH. NOTE: Publication of this article is sponsored by the American Ophthalmological Society TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00182929., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Progression of diabetic retinopathy in women with pregestational diabetes during pregnancy and postpartum.
- Author
-
Widyaputri F, Khong EWC, Rogers SL, Nankervis AJ, Conn JJ, Sasongko MB, Shub A, Fagan XJ, Guest D, Symons RCA, and Lim LL
- Abstract
Background: Diabetic retinopathy (DR) may worsen during pregnancy, but its course in the postpartum remains poorly understood. Understanding the natural history of DR during and after pregnancy can help determine when sight-threatening DR treatment should be administered., Methods: A prospective longitudinal cohort study recruited pregnant women with pre-existing type 1 (T1D) or type 2 diabetes from two tertiary Diabetes Antenatal Clinics in Melbourne, Australia. Eye examination results in early pregnancy, late pregnancy, and up to 12-months postpartum were compared to determine DR changes. Two-field fundus photographs and optical coherence tomography scans were used to assess DR severity., Results: Overall, 105 (61.4%) women had at least two eye examinations during the observation period. Mean age was 33.5 years (range 19-51); 54 women (51.4%) had T1D; 63% had HbA1c <7% in early pregnancy. DR progression rate was 23.8% (95% CI 16.4-32.6). Having T1D (RR 4.96, 95% CI 1.83-13.46), pre-existing DR in either eye (RR 4.54, 95% CI 2.39-8.61), and elevated systolic blood pressure (adjusted RR 2.49, 95% CI 1.10-5.66) were associated with increased risk of progression. Sight-threatening progression was observed in 9.5% of women. Among the 19 eyes with progression during pregnancy, 15 eyes remained stable, three eyes progressed, and only one eye regressed in the postpartum., Conclusions: Nearly 1 in 4 women had DR progression from conception through to 12-months postpartum; almost half of these developing sight-threatening disease. DR progression occurring during pregnancy was found to predominantly remain unchanged, or worsen, after delivery, with very few eyes spontaneously improving postpartum., (© 2024 The Author(s). Clinical & Experimental Ophthalmology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologists.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.